English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 903993      Online Users : 765
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
  • Adv. Search
    HomeLoginUploadHelpAboutAdminister Goto mobile version
    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/10552


    Title: Design, synthesis, and evaluation of thiazolidine-2,4-dione derivatives as a novel class of glutaminase inhibitors
    Authors: Yeh, TK;Kuo, CC;Lee, YZ;Ke, YY;Chu, KF;Hsu, HY;Chang, HY;Liu, YW;Song, JS;Yang, CW;Lin, LM;Sun, MW;Wu, SH;Kuo, PC;Shih, C;Chen, CT;Tsou, LK;Lee, SJ
    Contributors: Institute of Biotechnology and Pharmaceutical Research
    Abstract: Humans have two glutaminase genes, GLS (GLS1) and GLS2, each of which has two alternative transcripts: the kidney isoform (KGA) and glutaminase C (GAC) for GLS, and the liver isoform (LGA) and glutaminase B (GAB) for GLS2. Initial hit compound (Z)-5-((1-(4-bromophenyl)-2,5-dimethyl-1H-pyrrol-3-yl)methylene)thiazolidine-2,4- dione (2), a thiazolidine-2,4-dione, was obtained from a high throughput screening of 40000 compounds against KGA. Subsequently, a series of thiazolidine-2,4-dione derivatives was synthesized. Most of these were found to inhibit KGA and GAC with comparable activities, were less potent inhibitors of GAB, and were moderately selective for GLS1 over GLS2. The relationships between chemical structure, activity, and selectivity were investigated. The lead compounds obtained were found to (1) offer in vitro cellular activities for inhibiting cell growth, clonogenicity, and cellular glutamate production, (2) exhibit high concentrations of exposure in plasma by a pharmacokinetic study, and (3) reduce the tumor size of xenografted human pancreatic AsPC-1 carcinoma cells in mice.
    Date: 2017-07
    Relation: Journal of Medicinal Chemistry. 2017 Jul;60(13):5599-5612.
    Link to: http://dx.doi.org/10.1021/acs.jmedchem.7b00282
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0022-2623&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000405764900022
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85023743600
    Appears in Collections:[李秀珠] 期刊論文
    [鄒倫] 期刊論文
    [陳炯東] 期刊論文
    [石全(2014-2017)] 期刊論文
    [郭靜娟] 期刊論文
    [葉燈光] 期刊論文

    Files in This Item:

    File Description SizeFormat
    PUB28609101.pdf7104KbAdobe PDF478View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback